Transgender people planning a medical transition face decisions about family planning, fertility preservation, and how to access gender-affirming treatment.
AMA J Ethics. 2016;18(11):1119-1125. doi:
10.1001/journalofethics.2016.18.11.pfor2-1611.
Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.